Table 4.

Anxiety disorder.

	Study Design	Country	No.	Age Group	Disease	Daily Dosage (g/d)	Duration	Rating Scale	End Point
Hamazaki et al., 2005 [83]	Randomised, double-blind, placebo controlled trial	Japan	22	18–24 years	Healthy subjects	- EPA 400 mg/d + DHA 300 mg/d Or placebo	8 weeks	EP, NE, dopamine, cortisol and corticotropin concentration	PUFAs supplementation were associated with a decreased activation of the hypothalamic–pituitary–adrenal (HPA) axis.
Kiecolt-Glaser et al., 2011 [84]	Randomised, double-blind, placebo controlled trial	USA	68	21–29 years	Healthy subjects	EPA 2085 mg/d + DHA 348 mg/d or placebo	12 weeks	-Beck Anxiety Inventory	PUFAs supplementation were associated with 20% reduction in anxiety symptoms, without significant change in depressive symptoms.
Manos et al., 2018 [85]	Randomised, double-blind, placebo controlled trial	USA	24	12–21 years	- anxiety disorder and AN	- EPA 2120 mg/d + DHA 600 mg/d or placebo	12 weeks	- BAIT - CES-D - EAT-26	No evidence that omega-3 PUFA benefited anxiety.
Robinson et al., 2019 [86]	Randomised, double-blind, placebo controlled trial	USA	50	15–40 years	- early psychosis and anxiety	- EPA 740 mg/d and DHA 400 mg/d or placebo	16 weeks	- BPRS - SANS - CGI - SAFTEE-SI	Implementation with n-3 PUFAs was found mainly useful on depression-anxiety domain measured with the Brief Psychiatric Rating Scale (BPRS).

BAIT: Beck Anxiety Inventory-Trait; BPRS: Brief Psychosis Rating Scale; CES-D: Centre for Epidemiologic Studies Depression Scale; CGI Clinical Global Impressions; EAT-26: Eating Attitudes Test; SAFTEE-SI: Systematic Assessment for Treatment Emergent Events Specific Inquiry; SANS: Schedule for Assessment of Negative Symptoms.